TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06712004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevifibatide citrate injection
Description: Bevifibatide citrate injection should be diluted with 0.9% NaCl solution. After the completion of the study drug infusion, if a follow-up cranial NCCT/MRI within 48 hours shows no significant intracranial hemorrhage, all patients will be administered enteric-coated aspirin tablets (100mg, qd) and clopidogrel hydrogen sulfate tablets (75mg, qd) until day 90. All patients will be managed in accordance with the current guidelines for stroke management. The use of low molecular weight heparin for the prevention of deep vein thrombosis is permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevifibatide citrate injection
Description: Bevifibatide citrate injection should be diluted with 0.9% NaCl solution. After the completion of the study drug infusion, if a follow-up cranial NCCT/MRI within 48 hours shows no significant intracranial hemorrhage, all patients will be administered enteric-coated aspirin tablets (100mg, qd) and clopidogrel hydrogen sulfate tablets (75mg, qd) until day 90. All patients will be managed in accordance with the current guidelines for stroke management. The use of low molecular weight heparin for the prevention of deep vein thrombosis is permitted.
Study: NCT06696482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Escitalopram 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Study: NCT05343013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: GIven by PO
Study: NCT06143423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AP026 (TQA2226) for injection matching placebo
Description: AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AP026 (TQA2226) for injection matching placebo
Description: AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
Study: NCT06540014

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is made, groups are formed just due to the races.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is made, groups are formed just due to the races.
Study: NCT05717907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: suction catheter
Description: a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
Study: NCT04846517

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Treatment
Description: iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA
Study: NCT05005520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTRI-031
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to DTRI-031
Study: NCT05274685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haemodialysis
Description: continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
Study: NCT06696482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10 mg
Description: Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Study: NCT05953506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10506
Description: HS-10506 will be administered orally once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10506 Placebo
Description: Matching placebo will be administered orally once on Day 1.
Study: NCT06361472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextual Factors
Description: Bundle of contextual factors divided into three categories: professional, treatment, and healthcare setting features. Regarding the professional contextual factors, they include reputation, appearance, and positive attitudes. The treatment contextual factors encompass positive attitudes, verbal communication, non-verbal communication, empathetic therapeutic alliance, therapeutic touch, and the use of a mirror to show the patient what is being performed. Finally, the healthcare setting contextual factors feature a comfortable setting, adequate environmental conditions, and appropriate design.
Study: NCT06696846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-NK
Description: CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells. By using their unique target cell recognition mechanism, the target is accurately locked on specific antigen proteins, thereby enhancing the anti - tumor effect. Cord blood-derived CAR - NK cell products shorten the treatment time and are inexpensive. Multiple studies have confirmed the feasibility of CAR - NK cells in treating hematological tumors.~Blocking the CD70/CD27 signaling pathway plays an important role in inhibiting CD70 - positive tumors, such as refractory/relapsed T - cell lymphoma and acute myeloid leukemia. Pre - clinical studies in our laboratory have proved that CD70 CAR - NK can effectively inhibit the in - vivo and in - vitro proliferation of T - cell lymphoma and prolong survival.
Study: NCT06698068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-assisted therapy
Description: 15 equine therapy sessions, twice a week, over 7 to 8 weeks. Each session will last 60 minutes, including various activities such as emotional expression, contact with the horse, grooming, activities on foot or on horseback, and a debriefing time.
Study: NCT06398626

Intervention type: DRUG
Intervention: Etrasimod
Description: As provided in real world practice
Study: NCT06211257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dematerialized Personalized Care Plan (ePCP)
Description: Post-treatment support with standard support combined with dematerialized support
Study: NCT05523960

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No MBP
Description: No mechanical bowel preparation before operation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No MBP
Description: No mechanical bowel preparation before operation
Study: NCT06160388

Intervention type: DEVICE
Intervention: S53P4 Bioactive glass
Description: Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
Study: NCT05001191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
Study: NCT04836182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-AGT-LRx
Description: Multiple doses of IONIS-AGT-LRx will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Study: NCT06147258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: expressive writing
Description: A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
Study: NCT05425797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Prevention Practitioner Visit
Description: BETTER Intervention visit with PP which will take place in-person at the PP's office.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Call Prevention Practitioner Visit
Description: BETTER Intervention visit with PP which will take place virtually via a secure video system.
Study: NCT05995873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: unilateral transcranial photobiomodulation
Description: An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: unilateral transcranial photobiomodulation
Description: An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
Study: NCT04870034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT05385185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab or envafolimab
Description: combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
Study: NCT06002958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Horyzons USA
Description: Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
Study: NCT05425797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Prevention Practitioner Visit
Description: BETTER Intervention visit with PP which will take place via telephone.
Study: NCT04926324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Study: NCT05586724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone in continuous combination with oral estrogen
Description: Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone acetate in continuous combination with oral estrogen
Description: Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
Study: NCT05396950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP in conjunction with radiotherapy
Study: NCT04926324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiation
Description: Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
Study: NCT05098951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
Study: NCT03205137

Intervention type: DRUG
Intervention: subjects treated with telmisartan/hydrochlorothiazide
Description: subjects treated with telmisartan/hydrochlorothiazide

Intervention type: DRUG
Intervention: Subjects treated with Telmisartan and amlodipine
Description: Subjects treated with Telmisartan and amlodipine

Intervention type: DRUG
Intervention: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Description: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

Intervention type: DRUG
Intervention: subjects treated with telmisartan+amlodipine double pill
Description: subjects treated with telmisartan+amlodipine double pill
Study: NCT05674175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
Description: CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
Description: CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
Description: HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
Description: HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
Study: NCT05584371

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free Beta-hydroxybutyrate
Description: Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
Study: NCT04926324

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiation
Description: Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
Study: NCT06170489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 in combination with Toripalimab
Description: Participants will receive JS004 in combination with Toripalimab (200 mg/240 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine or gemcitabine
Description: Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
Study: NCT06500572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Landmark Guided Intercostobrachial Nerve Block
Description: In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Intercostobrachial Nerve Block
Description: The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serratus Plane Block
Description: The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
Study: NCT06103461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: Autologous fat grafted at contour defects with pigmentary changes
Study: NCT05588882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided LASIK
Description: Topography-guided utilizes topography mapping to perform the ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided
Description: Wavefront-guided utilizes aberrometry to perform the ablation
Study: NCT04920214

Intervention type: DIAGNOSTIC_TEST
Intervention: SonoVue
Description: CEUS examination was performed and corresponding image information of liver lesions was obtained.
Study: NCT06298630

Intervention type: OTHER
Intervention: Assessments
Description: Safety and efficacy assessments
Study: NCT05098470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1500-2000 mg per day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Long-acting insulin for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: Oral Glucokinase Activator 75 mg twice daily for 8 weeks